Our data suggested that the role of PGAM5 on NASH was only prominent with the presence of obesity since PGAM5 deletion only alleviated NASH in the HFHF model with excessive energy intake and systemic fat accumulation. Here, PGAM5 is linked to metabolic dysfunction-associated steatohepatitis.